Charles joined SV in 2018 and is an Associate in the biotech team. He helps form and fund companies developing transformational new medicines, particularly focusing on new company creation. Charles serves as a board observer at Autifony Therapeutics, and Mestag Therapeutics. He has helped SV invest in Imbria Therapeutics, as well as incubate and launch Mestag Therapeutics.
Charles carries out due diligence of new deals, and provides strategic, BD, and operational support to existing companies in the SV portfolio supporting them in bringing drugs from discovery to market.
Prior to joining SV, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences clients including SV portfolio companies.
Outside of SV, Charles is a keen chef, swimmer, and traveller.
MSci Human Genetics, University College London; specialization in the genetics of neurodegenerative disease and cancer biology. Chartered accountant (ACA).